Bioventus (BVS) vs Carlsmed (CARL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Carlsmed (CARL) has outperformed Bioventus (BVS) over the past year, gaining 39.5% versus a gain of 36.5%. Bioventus is the larger company by market cap ($676.5 million vs $477.4 million), about 1.4 times the size, while Carlsmed is growing revenue faster (+85.9% vs -0.9%). Bioventus converts more of its revenue into profit, with a net margin of 4.0% versus -58.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BVS | CARL |
|---|---|---|
| Share price | $9.88 | $17.42 |
| Market cap | $676.53M | $477.38M |
| 1-day change | -0.70% | +1.16% |
| YTD return | +32.80% | +41.05% |
| 1-year return | +36.46% | +39.47% |
| 5-year return | -21.02% | — |
| P/E ratio (TTM) | 12.20 | — |
| Forward P/E | 11.13 | — |
| EPS (TTM) | $0.81 | $-1.13 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $568.09M | $50.51M |
| Revenue growth (YoY) | -0.91% | +85.94% |
| Net income (latest FY) | $22.73M | $-29.63M |
| Gross margin | 68.33% | 75.31% |
| Operating margin | 9.50% | -60.53% |
| Net margin | 4.00% | -58.67% |
| 52-week high | $15.89 | $19.15 |
| 52-week low | $7.02 | $8.50 |
| Distance from 52-week high | -37.83% | -9.05% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +68.02% | +26.29% |
| Average volume | 536.81K | 112.80K |
| Shares outstanding | 68.47M | 27.40M |
| Employees | 960 | 127 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Bioventus is more profitable, keeping 4.0 cents of every revenue dollar as net income versus -58.7 cents for Carlsmed.
- Carlsmed grew revenue faster in its latest fiscal year (+85.94% vs -0.91%).
About Bioventus
BVS stock →Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle.
Health Care · Medical/Dental Instruments · 960 employees
About Carlsmed
CARL stock →Carlsmed, Inc., a commercial-stage medical technology company, designs, manufactures, and markets AI-enabled personalized spine surgery solutions. The company develops aprevo, a comprehensive technology platform for spine fusion surgery procedures.
Health Care · Medical/Dental Instruments · 127 employees
BVS vs CARL FAQ
Which is bigger, Bioventus or Carlsmed?
Bioventus (BVS) is larger, with a market capitalization of $676.53M compared with $477.38M for Carlsmed (CARL).
Which stock has performed better over the past year, BVS or CARL?
CARL returned +39.47% over the past 12 months, compared with +36.46% for BVS (price return, excluding dividends). Past performance does not predict future results.
Are Bioventus and Carlsmed in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.